Comparing oxygen demand in critical covid-19 patients using single versus double doses of tocilizumab

References

1. 1.↵
   Wolrd Health Organization. COVID 19 Public Health Emergency of International Concern (PHEIC). Global research and innovation forum: towards a research roadmap. [Updated 2020; accessed 2022 Dec 20]. Available from: https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum
2. 2.↵
   1. Gupta S,
   2. Hayek SS,
   3. Wang W,
   4. Chan L,
   5. Mathews KS,
   6. Melamed ML, et al.

   STOP-COVID Investigators. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 2020; 180: 1436–1447.

   OpenUrl
3. 3.↵
   1. Chen N,
   2. Zhou M,
   3. Dong X,
   4. Qu J,
   5. Gong F,
   6. Han Y, et al.

   Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–513.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Al-Baadani A,
   2. Eltayeb N,
   3. Alsufyani E,
   4. Albahrani S,
   5. Basheri, S,
   6. Albayat H, et al.

   Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes. J Infect Public Health 2021; 14: 1021–1027.

   OpenUrl
5. 5.↵
   1. AlQahtani H,
   2. AlBilal S,
   3. Mahmoud, E,
   4. Aldibasi O,
   5. Alharbi A,
   6. Shamas N, et al.

   Outcomes associated with tocilizumab with or without corticosteroid versus dexamethasone for treatment of patients with severe to critical COVID-19 pneumonia. J Infect Public Health 2022; 15: 36–41.

   OpenUrl
6. 6.↵
   1. Sarfraz A,
   2. Sarfraz Z,
   3. Sarfraz M,
   4. Aftab H,
   5. Pervaiz Z.

   Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies. Turkish J Med Sci 2021; 51: 890–897.

   OpenUrl
7. 7.↵
   1. Rosas IO,
   2. Bräu N,
   3. Waters M,
   4. Go RC,
   5. Hunter BD,
   6. Bhagani S.

   Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med 2021; 384: 1503–1516.

   OpenUrlPubMed
8. 8.↵
   1. Al Sulaiman K,
   2. Aljuhani O,
   3. Bin Salah K,
   4. Korayem GB,
   5. Eljaaly K,
   6. Al Essa M, et al.

   Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): a two-center, retrospective cohort study. J Crit Care 2021; 66: 44–51.

   OpenUrl
9. 9.↵
   1. Gupta, S,
   2. Wang W,
   3. Hayek SS,
   4. Chan L,
   5. Mathews KS,
   6. Melamed ML, et al.

   STOP-COVID Investigators. Association between early treatment with tocilizumab and mortality among critically Ill patients with COVID-19. JAMA Intern Med 2021; 181: 41.

   OpenUrlPubMed
10. 10.↵
    1. Durán-Méndez A,
    2. Aguilar-Arroyo AD,
    3. Vivanco-Gómez E,
    4. Nieto-Ortega E,
    5. Pérez-Ortega D,
    6. Jiménez-Pérez C, et al.

    Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study. Sci Rep 2021; 11: 19728.

    OpenUrl
11. 11.↵
    1. Ledford H.

    How does COVID-19 kill? Uncertainty is hampering doctors’ ability to choose treatments. Nature 2020; 580: 311–313.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Rees EM,
    2. Nightingale ES,
    3. Jafari Y,
    4. Waterlow NR,
    5. Clifford S,
    6. Pearson CAB, et al.

    COVID-19 length of hospital stay: a systematic review and data synthesis. COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Med 2020; 18: 1–22.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Horb PW,
    2. Campbell M,
    3. Staplin N,
    4. Spata E,
    5. Emberson JR, et al.

    Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. Lancet 2021; 397: 1637–1645.

    OpenUrlCrossRefPubMed